Fred Hutch Innovation Lab
@hutchinnovation.bsky.social
FHIL is leading the in-house development and early adoption of powerful new single-cell and spatial technologies to spur discoveries in cancer immunotherapy.
One might expect paired chain proportions to differ, but the SFFS sample had a 69% paired chain recovery, similar to its fresh F1 counterpart, and a slightly higher proportion of TRA and TRβ chains. (5/7)
September 2, 2025 at 8:05 PM
One might expect paired chain proportions to differ, but the SFFS sample had a 69% paired chain recovery, similar to its fresh F1 counterpart, and a slightly higher proportion of TRA and TRβ chains. (5/7)
T-cell composition was similar for the SSFS and fresh F1 samples, including T-regs. Some unresolved cells were seen in each. (4/7)
September 2, 2025 at 8:05 PM
T-cell composition was similar for the SSFS and fresh F1 samples, including T-regs. Some unresolved cells were seen in each. (4/7)
The SFFS sample had a 7% decrease in the median genes at 20k reads/cell (blue) compared to fresh samples (red), which tracked with example data from the demonstrated protocol. (3/7)
September 2, 2025 at 8:05 PM
The SFFS sample had a 7% decrease in the median genes at 20k reads/cell (blue) compared to fresh samples (red), which tracked with example data from the demonstrated protocol. (3/7)
Our goals were twofold: Test sorting DSP fixed cells in sheath fluid & compare the performance of SFFS cells to fresh samples. Using a standard donor PBMC (F1), we made GEM-X 5’ and VDJ libraries from DSP fixed and sorted T cells to compare with previous data and saw similar cell recovery. (2/7)
September 2, 2025 at 8:05 PM
Our goals were twofold: Test sorting DSP fixed cells in sheath fluid & compare the performance of SFFS cells to fresh samples. Using a standard donor PBMC (F1), we made GEM-X 5’ and VDJ libraries from DSP fixed and sorted T cells to compare with previous data and saw similar cell recovery. (2/7)